Navigation Links
Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
Date:3/10/2008

PINE BROOK, N.J., March 10 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced the appointment of Robert Gundel, Ph.D., M.B.A., as Vice President of Research.

Elizabeth G. Posillico, Ph.D., President and Chief Executive Officer, commented on the appointment, "On behalf of Elusys' Board of Directors and management, I am very pleased to welcome Bob to our executive management team. As Vice President of Research, he will play a key role in helping to further develop and advance our corporate and scientific strategies. With more than twenty-five years of experience in developing monoclonal antibody-based products from both the biotech and pharmaceutical sectors, Dr. Gundel will lead our existing R&D team to further the development of our antibody based products for the treatment of infectious disease. He will also use his expertise to evaluate new product opportunities and will play a key leadership role in managing our existing and future R&D collaborations."

Prior to joining Elusys, Dr. Gundel held executive management positions at a number of leading biopharmaceutical companies including, Bayer, Chiron, XOMA and ARIUS. Most recently, Dr. Gundel served as Chief Scientific Officer at ARIUS Research, Inc., a biotechnology company focused on the discovery and development of therapeutic antibodies for the treatment of cancer and other diseases. At ARIUS, he managed the drug discovery and development programs and worked to broaden the company's targeted therapeutic areas by identifying and developing new programs outside of oncology. He also identified new technologies to keep the company ahead of the curve for therapeutic drug discovery, development and manufacturing.

Previously, Dr. Gundel was Vice President, Preclinical Research and Scientific Corporate Development at XOMA (US), LLC, a biote
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
2. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
3. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
4. ExonHit Therapeutics - 2007 Financial Results
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
7. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
8. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
9. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
10. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
11. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline ... The rate of HIV infection and the number of deaths ... a positive rate across the globe. It has been estimated ... to 1.5 in 2013, with the rates for children being ... in the infection rates has been the improved access to ...
(Date:8/18/2014)... DALLAS , August 18, 2014 ... "Membrane Bioreactor Systems Market, By Application (Municipal Wastewater ... Fiber, Flat Sheet and Multi Tubular), By Configuration ... to 2019", published by MarketsandMarkets, The market for ... million by 2019, growing at a CAGR of ...
(Date:8/18/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... on Form 10 with the U.S. Securities and ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form ...
(Date:8/18/2014)... , 18. August 2014 Vier ... eine internationale klinische Studie auf, in der ... Linse soll das Sehvermögen bei allen Entfernungen ... Operation möglicherweise keine Lese- oder Gleitsichtbrille mehr ... Namen FluidVision Accommodating Intraocular Lens ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... Holdings, Inc. (NYSE: ZMH ; SWX: ZMH) announced today ... broadcast live over the Internet on Thursday, July 23, 2009, at ... results will be made available at 7:00 a.m. the morning of ... be accessed via Zimmer,s Investor Relations website at ...
... Pa. and NEWTON, Mass., June 30 Microfluidics, ... (OTC Bulletin Board: MFLU), and Particle Sciences Inc. ... biopharmaceutical companies leverage the most advanced and reliable ... and commercialize Active Pharmaceutical Ingredients (APIs). , ...
... June 30 Hospira, Inc. (NYSE: HSP ... today announced agreements with MedAssets on intravenous (I.V.) solutions ... agreement for infusion devices. The five-year MedAssets agreements are ... and equipment, and July 1, 2009, for infusion devices. ...
Cached Biology Technology:Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 2Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 3Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2
(Date:8/19/2014)... MA -- MIT chemical engineers have devised a new ... are released slowly over a few weeks. When applied ... the body to rapidly form new bone that looks ... type of coated scaffold could offer a dramatic improvement ... involves transplanting bone from another part of the patient,s ...
(Date:8/19/2014)... today,s crocodiles colonised the seas during warm phases and ... Anglo-French study which establishes a link between marine crocodilian ... period of more than 140 million years. , ... Universit de Lyon, France and formerly from the University ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals that ...
(Date:8/19/2014)... A team of UTSA researchers has been awarded a ... Technology and Training (NCPTT), an office of the National ... The grant will fund a one-year study of the ... of historic homes in hot, humid climates. , Radiant ... or attics that reflect heat back, thereby reducing the ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3Evolution of marine crocodilians constrained by ocean temperatures 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Angeles New evidence from the University of Southern California ... that help compile small bits of information in order to ... professor of psychology in the area of brain and cognitive ... Public Library of Science journal, PLoS ONE. It ...
... MA--Boston University School of Medicine (BUSM) will present The Sixth ... 14, 2007 at noon. The annual lecture is in honor ... in BUSMs Pulmonary Center. Kim Hanson, along with her ... the second plane that struck the World Trade Center on ...
... University of Oregon has received a $1.6 million grant ... effects of exposure to precisely engineered nanoparticles that are ... three-year grant from the Keck Foundations medical research program ... Andy Berglund, all UO professors of chemistry; UO biology ...
Cached Biology News:Shape encoding may start in the retina 2Lecture to honor victim of Sept. 11 tragedy 2Keck Foundation funds study of biological interactions with nanomaterials 2
...
... measures NOS activity by monitoring the conversion ... is simple, sensitive, and specific for NOS ... crude and purified enzyme preparations. The kit ... total reactions. Radiolabeled arginine and NADPH are ...
Human TSLP MAb (Clone 258136)...
Human Complement Component C5a MAb (Clone 295003)...
Biology Products: